Brand & Product Security

Articles

Conference presentation explores groundbreaking topics impacting the pharma industry.

Fruquintinib (Fruzaqla) is a significant new therapy for patients who have had limited options to treat metastatic colorectal cancer.

Conference session discusses the drivers, practical considerations, success factors, and landscape for next-generation pharmacy innovation.

Ayala Pharmaceuticals’ AL102 is a gamma secretase inhibitor being studied to treat patients with desmoid tumors.

Surge acted as a precursor for the RSV-marketed drug landscape in 2023, says GlobalData.

Value is attributed to the rise in counterfeit cases and ongoing regulations surrounding anti-counterfeit packaging. 

Pharma Commerce converges on Nation's Capital for HDA Traceability Seminar.

The agency differentiates between software that has a notable impact on the effectiveness and safety of drug use.

PBM transparency and data reporting requirements are likely to be part of a larger healthcare bill that Congress will work on this fall.

Pharma Commerce provides a synopsis of the presentation. 